复杂尿路感染分类与治愈检测共识声明
该共识声明分析研究人员对FDA复杂尿路感染指南的依从性,并通过文献综述、风险因素评估和Delphi共识流程,发现依从性差且研究报告异质性高,导致高偏倚风险,从而质疑复杂尿路感染作为独立研究实体的概念。
要点
- 对FDA复杂尿路感染指南的依从性差,研究、患者和病原体特征报告异质性显著。
- 上述异质性导致解读和比较研究结果时存在高偏倚风险。
- 质疑复杂尿路感染作为具有自身研究指南的有意义实体的概念。
核心结论
- 质疑复杂尿路感染作为具有自身研究指南的有意义实体的概念。
研究设计与样本
- 采用三步法:对复杂尿路感染全文文章进行文献综述;评估治疗失败风险因素的重要性,包括统计评估有风险因素的患者可能如何扭曲治疗效果;在多学科小组中进行Delphi共识流程。
主要发现
- 评估显示对FDA复杂尿路感染指南的依从性差。
- 研究、患者和病原体特征报告存在显著异质性。
- 上述问题导致解读和比较研究结果时存在高偏倚风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complicated urinary tract infections denote an important research field for new antibiotics against Gram-negative pathogens. There is, however, increasing concern that this disease entity is too vaguely defined, leading to heterogeneous study populations and risk of bias. We analysed researchers' adherence to the US Food and Drug Administration (FDA) guidance on complicated urinary tract infection and assessed risk of bias using a three-step procedure: literature review of full-text articles on complicated urinary tract infection; assessment of the importance of risk factors for treatment failure, including statistical evaluation of how patients with risk factors might skew treatment effects; and a Delphi consensus process in a multidisciplinary group. Our evaluation showed poor adherence to FDA guidance on complicated urinary tract infection and significant heterogeneity in the reporting of study, patient, and pathogen characteristics, leading to a high risk of bias when interpreting and comparing study findings. We therefore question the concept of complicated urinary tract infection as a meaningful entity with its own study guidance.
引用
- Bjerklund Johansen TE, Bahrs C, Bruyere F, et al. Consensus position statement on advancing the classification of patients and tests of cure in studies of antibiotic treatment of complicated urinary tract infections. Lancet Infect Dis. 2025. PMID: 40378860. doi:10.1016/S1473-3099(25)00142-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。